May 29, 2014 by Michael Douglass and Dave Williamson$1.2 Billion Partnership: Key TakeawaysBristol inks yet another deal -- this time with CytomX
May 29, 2014 by Michael Douglass and Dave WilliamsonCould This be Pfizer's Best Incoming Drug?Unmet medical need, potentially strong data, and a large potential market -- is this drug the best Pfizer's got in development?
May 28, 2014 by Michael Douglass and Dave WilliamsonShould Stryker Buy Smith & Nephew?Why the deal might actually make great sense.
May 28, 2014 by Michael Douglass and Dave Williamson1.4 Billion Reasons Valeant Thinks It's Got AllerganAnd in this case, it's Valeant selling instead of buying.
May 28, 2014 by Michael Douglass and Dave WilliamsonThe Cranberry Juice of Biotech StocksA lot of pharmas seem very interested in this company.
May 28, 2014 by Michael Douglass and Dave WilliamsonBetter Buy: BioCryst vs. DyaxBoth rose on great news yesterday. Which is the better buy?
May 27, 2014 by Michael Douglass and Dave WilliamsonDividend Aristocrat Medtronic's Earnings Report: Key TakeawaysAnother good, solid earnings report. What you need to know.
May 25, 2014 by Michael Douglass and Dave WilliamsonWas the Obamacare Panic Overblown?As more data comes out, the Obamacare picture looks better and better.
May 24, 2014 by Michael Douglass and Dave Williamson3 Thoughts for Investors on the MERS OutbreakMERS has been a major headline lately -- is there any way to get involved in helping find a cure or a vaccine?
May 23, 2014 by Michael Douglass and Dave WilliamsonIs It Time to Buy MannKind?Even if the FDA approves Afrezza, there are still plenty of questions about the stock and its opportunity.
May 23, 2014 by Michael Douglass and Dave WilliamsonBetter Bad News Buy: Ariad Pharmaceuticals vs. ExelixisThese two stocks are a long way from their 52-week highs. Which one's the better deal?
May 23, 2014 by Michael Douglass and Dave WilliamsonCan This Drug Strengthen Pfizer Sales?Could Pfizer's PCSK9 drug bococizumab help drive future sales?
May 22, 2014 by Michael Douglass and Dave Williamson$1.1 Billion Settlement: Winners and LosersWho won and lost in the end?
May 22, 2014 by Michael Douglass and Dave WilliamsonWhy Bayer Sold This Division to Boston ScientificWhy this acquisition made sense for both sides.
May 20, 2014 by Michael Douglass and Dave WilliamsonClovis Snags FDA Designation: What's Next?The coveted breakthrough designation comes through for CO-1686.
May 20, 2014 by Michael Douglass and Dave WilliamsonUp 7%: Insmed's Data Still MixedInsmed noted some good news in culture conversion, but is that really the big takeaway?
May 20, 2014 by Michael Douglass and Dave WilliamsonGood Idea? Incyte and AstraZeneca Team UpAnother cancer research team-up by Incyte and Astra.
May 20, 2014 by Michael Douglass and Dave WilliamsonWhat Bristol and Celldex's Team-Up Means for InvestorsCancer research as a team sport.
May 19, 2014 by Michael Douglass and Dave WilliamsonDown 12%: Will AstraZeneca Negotiate?Is this deal done for good?
May 17, 2014 by Michael Douglass and Dave WilliamsonGoogle vs. Samsung: The Ultimate Biotech ShowdownThese two tech companies are getting involved in a pretty surprising area.
